Stuart Weisbrod and Jacob Gottlieb have run separate funds for almost two decades, but now they will be under one roof. These two who are titans in the healthcare investing have known each other well after working together at Merlin Biomed Group. At the moment they will be sharing an office looking forward at a future collaboration in the making.
Weisbrod is a co-founder of Merlin which came into existence in 1998. Merlin is an investment organization which is focusing on the healthcare field including portfolios in the medical device, pharmaceuticals, healthcare services, and biotechnology. Weisbrod has a proven record in biotechnology and healthcare investment with positions Harpel Partners, Oracle Partners, Prudent-Bache Securities, and Merrill Lynch. In addition to this, the academic qualifications of Weisbrod are desirable. He earned his Ph.D. from Princeton University in Biochemistry in 1990. He holds an MBA from the University of Colombia in finance. Besides, he received his BA from Colgate University in Chemistry.
After winding up Merlin, Weisbrod has developed a new investment organization by the name of Iguana Healthcare Partners. The strategy behind this investment company is similar to that of Merlin. The approach concentrates on public organizations in the healthcare sector. This involves healthcare information, healthcare services, diagnostic, medical device, biotechnology, and pharmaceutical organizations.
Like Weisbrod, Gottlieb decided to come up with his company after leaving Merlin. After working in the financial sector for years, he established Visium Asset Management with an initial capital of $300 million. The company progressed so quickly to $2.5 billion in 2008. The company survived the 2008 financial crisis, and this made Gottlieb grow it into a hedge fund worth $8 billion. The company has its offices in London, San Francisco, and New York. Currently, the organization has around 200 workers. However, despite the success that Visium had enjoyed for over a decade, the organization came down in 2016. The company came down after three of its directors were accused of mismarking and insider trading.
With these two former colleagues as well as highly successful entrepreneurs in finance, Weisbrod, and Gottlieb working under the same office, the sector is sure to experience some exciting changes as well as significant outcomes for opportunities in healthcare investment. Gottlieb is ready with his next business, Altium Capital as he winds up everything to do with Visium. Altium like Visium is also a hedge fund. Altium is Jacob Gottlieb’s fresh that after carefully considering his next step after Visium.